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The antagonism of PAF effects by WEB 2086 and the receptor binding of PHIWEB 2086 were investigated in isolated 
human neutrophils. WEB 2086 inhibited PAF-induced p-glucuronidase release and PHIWEB 2086 bound specifically to 
high-affinity sites on the cells. Close concordance between affinity constants for WEB 2086 from functional and radio- 
ligand-binding studies suggests that WEB 2086 interacts with the neutrophil PAF receptors and that PHIWEB 2086 may 
be a useful igand in investigation of these receptors. 
Platelet-activating factor; Platelet-activating factor antagonist; Platelet-activating factor receptor; (Neutrophil) 
1. INTRODUCTION 
Platelet-activating factor (PAF) is a potent 
mediator of inflammation generated by platelets, 
neutrophils, eosinophils, macrophages and vascu- 
lar endothelial cells. It shows several pharmacolog- 
ical actions such as aggregation of platelets and 
neutrophils, bronchoconstriction, hypotension, in- 
crease in vascular permeability and chemotaxis of 
inflammatory cells [ 1,2]. 
There is much evidence to suggest he existence 
of specific receptors for PAF on the plasma mem- 
branes of target cells [3]. Specific binding of PAF 
has been reported in membrane preparations [4] as 
well as in various tissues and cells, including 
human neutrophils [5]. Binding studies with 
[‘H]PAF have often proved difficult, especially 
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with leukocytes, due to the binding of the 
radioligand to low-affinity, high-capacity binding 
sites and the uptake and metabolism of the 
radioligand [5]. It has been hoped that the develop- 
ment of specific PAF antagonists may overcome 
these difficulties and a number of antagonists have 
been developed recently. 
The thieno-triazolodiazepine WEB 2086 has 
been shown to be a potent and specific PAF an- 
tagonist both in vitro and in vivo [6]. Using the 
tritiated form of this compound we have suc- 
cessfully identified PAF receptors in human 
platelets [7]. In the presence study we have in- 
vestigated WEB 2086 as an antagonist of PAF- 
induced degranulation of human neutrophils 
(measured as ,&glucuronidase release) 
radioligand to label PAF receptors in 
cells. 
2. MATERIALS AND METHODS 
and as a 
the same 
Leukocytes were obtained from acid citrate dextrose an- 
ticoagulated blood of normal healthy volunteers as previously 
described [8] and resuspended in Hepes-BSA buffer consisting 
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of Hank’s balanced salt solution supplemented with 20 mM 
Hepes and 3.5 g/l bovine serum albumin (BSA), pH 7.2. For 
radioligand-binding studies cells were suspended in the binding 
assay buffer described previously [7]. 
Neutrophil suspensions (7.5 x lo6 cells/ml, 97 + 0.4% pure), 
pre-incubated at 37°C for 10 min in the presence of 5 ag/ml 
cytochalasin B, were incubated in a final volume of 1 ml Hepes- 
BSA buffer containing PAF, or alternative stimuli, at the in- 
dicated concentrations, with or without WEB 2086 or the PAF- 
antagonist BN 52021 [9] at 37’C for 20 min. Reactions were 
halted by centrifugation at 9000 x g for 2 min. ,&Glucuronidase 
was assayed in the cell supernatants by a modification of the 
method previously described [8] using p-nitrophenyl-P-D- 
glucuronide as substrate. Absorbance was measured at 399 nm 
and ,&glucuronidase activity was expressed as a percentage of 
the total cell content of the enzyme, defined as activity released 
from cells treated with 0.1% Triton X-100 (v/v) for 20 min at 
37°C. The cytoplasmic enzyme lactate dehydrogenase (LDH) 
was assayed in supernatants as previously described [8]. 
Binding of [‘HIWEB 2086 to human neutrophils was 
measured by a procedure similar to that described for human 
platelets [7]. 5 x 106-1.5 x 10’ cells were added to a final 
volume of 1 ml of binding assay buffer containing the 
radioligand at the indicated concentrations and incubated with 
continuous shaking at 25°C for 90 min. In competition ex- 
periments the final concentration of [‘HIWEB 2086 was 20 nM. 
Other substances were added as indicated. Nonspecific binding 
was determined in the presence of 1OpM WEB 2086 or 1 ,uM 
PAF. All incubations were conducted in triplicate. Bound and 
free radioligands were separated by rapid filtration through 
Whatman GF/C glass fibre filters pre-soaked in 1% BSA for 
1 h. Filters were then washed twice with 4 ml of ice-cold bind- 
ing assay buffer. 
3-[4-(Chlorophenyl)-9-methyl-H-thieno[3,2-~[l,2,4]triazolo- 
[4,3-a][l,4]diazepin-2-yl](4-morpholinyl)-l-propanone (WEB 
2086) and [‘HIWEB 2086 solution (15 Ci/mmol) were kindly 
donated by Boehringer Ingelheim (Ingelheim am Rhein, FRG). 
PAF and lyso-PAF (both hexadecyl form) were purchased from 
Bachem Feinchemikalien AC (Bubendorf, Switzerland). BN 
52021 was a gift from Dr P. Braquet (Ipsen Institute for 
Therapeutic Research, Le Plessis Robinson, France). Ficoll- 
Paque was purchased from Pharmacia Laboratory Separation 
Division, Uppsala, Sweden. All other chemicals were from 
standard commercial sources. 
3. RESULTS 
PAF induced a concentration-dependent release 
of P-glucuronidase from human neutrophils with 
an EGO of 138 nM (geometric mean, 95% con- 
fidence limits 55-346 nM, n = 6) whilst the inac- 
tive precursor and metabolite lyso-PAF caused no 
significant release at concentrations up to 10pM. 
LDH release was in no case greater than IO%, in- 
dicating no significant cytolysis. WEB 2086 and 
BN 52021 caused parallel rightward shifts of the 
PAF concentration-response curve (fig. 1); Schild 
analysis of the shifts gave a KB value for WEB 
2086 of 11.9 nM (6.7-21 nM, n = 3) and for BN 
52021 of 359 nM (n = 2). WEB 2086, at a concen- 
tration of 10 pM, did not inhibit degranulation in- 
duced by PMA or fMLP. 
Specific binding of [3H]WEB 2086 to human 
neutrophils was maximal at 25°C and declined at 
higher as well as lower temperatures. In the 
absence of any competing drug the isotherm con- 
-8 -6 -5 
Fig. 1. PAF-induced &glucuronidase release from human neutrophils in the absence of antagonist (0) and in the presence of WEB 
2086: 5 nM (A), 20 nM (0) and 50 nM (0). Inset: Schild plot of the same data. Data are from one representative experiment (mean 
results given in text). 
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Fig.2. Specific (0) and nonspecific (0) binding of 13H]WEB 2086 to human neutrophils. Inset: Scatchard plot of the same data. Data 
are from one representative xperiment (mean results given in text). 
formed to a simple hyperbola (fig.2). The derived 
Scatchard plot was linear, indicating a homogene- 
ous population of non-interacting binding sites. 
The KD was 18.9 f 0.6 nM (arithmetic mean f SE, 
n = 5) and the B,,, was 670 + 34 fmol/lO’ cells, 
corresponding to 40000 f 2000 sites/cell. The ratio 
of the calculated rate constants for dissociation (K2 
= 1.39 min-’ at 25°C) and association (KI = 9.3 x 
10’ min-’ -M-l) of [3H]WEB 2086 with human 
neutrophils gave a kinetically derived estimate of 
KD of 15 nM. From competition experiments the 
KI of WEB 2086 for inhibition of [3H]WEB 2086 
binding was 16.3 nM (11.3-23.7 nM, n = 3) and 
the slope factor @H) of the competition curves was 
0.98 + 0.03, indicating again homogeneity of the 
binding sites. BN 52021 competed for [3H]WEB 
2086-binding sites with a KI of 300 nM. The KI 
value of PAF was 170 pM (1 lo-260 pM, n = 3), 
whereas lyso-PAF did not compete for [3H]WEB 
2086-binding sites at concentrations up to 10 PM. 
4. DISCUSSION 
In the present report we have shown that WEB 
2086 is a specific and competitive antagonist of 
PAF-induced azurophil granule enzyme release 
from human neutrophils with an antagonist affini- 
ty constant (KB) of 11.9 nM against PAF ad shows 
no antagonistic action against two other stimuli of 
neutrophil degranulation (PMA and fMLP). We 
have also described direct radioligand binding of 
[3H]WEB 2086 to specific sites on these cells: the 
dissociation constant (KD) calculated from 
[3H]WEB 2086 saturation isotherms was 18.9 nM 
and the kinetically derived KD was 15 nM. The in- 
hibition constant (KI) for displacement of 
[3H]WEB 2086 from its binding sites by WEB 2086 
was 16.3 nM, which is close to both the KB and KD 
values. The KB of 359 nM for BN 52021 is also 
similar to the KI of 300 nM. The measures of WEB 
2086 affinity from functional and radioligand- 
binding experiments, therefore, are in close 
agreement. 
Direct radioligand-binding studies using [3H]- 
PAF have identified a high-affinity PAF-binding 
site with a KD of 220 pM and B,,, corresponding 
to 1100 sites/cell [5]. We have demonstrated a 
PAF antagonist-binding site for which PAF has a 
KI of 170 pM which is in close agreement with the 
KD for [3H]PAF. However, our B,,, of 40000 sites 
per cell is markedly different from the reported 
density of [3H]PAF-binding sites. It is possible that 
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with [3H]PAF may reflect a down-regulation of 
receptors after incubation with the radiolabelled 
agonist. 
The selectivity of the PAF antagonism by WEB 
2086, the specificity of the binding of [3H]WEB 
2086 and the concordance of the indices of recep- 
tor affinity of WEB 2086 obtained from functional 
and radioligand-binding studies lead us to con- 
clude that, in human neutrophils, WEB 2086 exerts 
its PAF antagonistic actions through direct in- 
teraction with the PAF receptor. WEB 2086 and 
the specific antagonist radioligand t3H]WEB 2086 
will prove useful in efforts to elucidate the 
physiological role and mechanism of action of 
PAF. 
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